We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Medically reviewed by Lindsay Cook, PharmD Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings report. The company traded as high as $26.69 and last traded at $26.62.

specifically the migraine headache treatment Nurtec ODT, according to the Florida Office of the Attorney General. In the settlement agreement from the U.S. Department of Justice, it states health ...